keyword
https://read.qxmd.com/read/38635938/clonal-hematopoiesis-and-therapy-related-myeloid-neoplasms-after-autologous-transplant-for-hodgkin-lymphoma
#1
JOURNAL ARTICLE
Chengcheng Yan, Melissa A Richard, Christopher J Gibson, Jianbo He, Alysia Bosworth, David K Crossman, Purnima Singh, Lindsey Hageman, Rashi Kalra, Saro H Armenian, Julie Vose, Daniel J Weisdorf, Benjamin L Ebert, Yutaka Yasui, Stephen J Forman, Ravi Bhatia, Smita Bhatia
PURPOSE: Therapy-related myeloid neoplasm (t-MN) is a life-threatening complication of autologous peripheral blood stem cell transplantation (aPBSCT) for Hodgkin lymphoma (HL). Although previous studies have reported an association between clonal hematopoiesis (CH) in the infused PBSC product and subsequent post-aPBSCT risk of t-MN in patients with non-HL, information about patients with HL treated with aPBSCT is not available. METHODS: We constructed a retrospective cohort of 321 patients with HL transplanted at a median age of 34 years (range, 18-71)...
April 18, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38635903/cd58-alterations-govern-antitumor-immune-responses-by-inducing-pd-l1-and-ido-in-diffuse-large-b-cell-lymphoma
#2
JOURNAL ARTICLE
Xiyue Xu, Yidan Zhang, Yaxiao Lu, Xiaoyan Zhang, Cuicui Zhao, Jiesong Wang, Qingpei Guan, Yingfang Feng, Meng Gao, Jingwei Yu, Zheng Song, Xia Liu, Zahra Golchehre, Lanfang Li, Weicheng Ren, Qiang Pan-Hammarström, Huilai Zhang, Xianhuo Wang
Recurrent abnormalities in immune surveillance-related genes affect the progression of diffuse large B-cell lymphoma (DLBCL) and modulate the response to therapeutic interventions. CD58 interacts with the CD2 receptor on T cells and natural killer (NK) cells and is recurrently mutated and deleted in DLBCL, suggesting it may play a role in regulating antitumor immunity. Herein, we comprehensively analyzed the genomic characteristics of CD58 through targeted next-generation sequencing, RNA-sequencing, whole-exome sequencing, and single-cell RNA-sequencing in patients with newly diagnosed DLBCL...
April 18, 2024: Cancer Research
https://read.qxmd.com/read/38635786/primary-large-b-cell-lymphomas-of-immune-privileged-sites
#3
JOURNAL ARTICLE
Mark Roschewski, James D Phelan, Elaine S Jaffe
Diffuse large B-cell lymphoma (DLBCL) encompasses a diverse spectrum of aggressive B-cell lymphomas with remarkable genetic heterogeneity and myriad clinical presentations. Multiplatform genomic analyses of DLBCL have identified oncogenic drivers within genetic subtypes that allow for pathologic subclassification of tumors into discrete entities with shared immunophenotypic, genetic, and clinical features. Robust classification of lymphoid tumors establishes a foundation for precision medicine and enables the identification of novel therapeutic vulnerabilities within biologically homogeneous entities...
April 18, 2024: Blood
https://read.qxmd.com/read/38635762/real-world-and-clinical-trial-outcomes-in-large-b-cell-lymphoma-with-axicabtagene-ciloleucel-across-race-and-ethnicity
#4
JOURNAL ARTICLE
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Armin Ghobadi, Sairah Ahmed, David B Miklos, Miguel-Angel Perales, Javier Munoz, Warren B Fingrut, Martina Pennisi, Jordan Gauthier, Mazyar Shadman, Lohith Gowda, Abu-Sayeef Mirza, Muhammad Bilal Abid, Sanghee Hong, Navneet S Majhail, Mohamed A Kharfan-Dabaja, Arushi Khurana, Talha Badar, Yi Lin, N Nora Bennani, Megan M Herr, Zhen-Huan Hu, Hailin Wang, Anjani Baer, Elande Baro, Harry Miao, Clare Spooner, Hairong Xu, Marcelo C Pasquini
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting the use of axi-cel in patients with LBCL, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world setting, 1290 patients with R/R LBCL who received axi-cel between 2017-2020 were identified from the Center for International Blood and Marrow Transplant Research database; 106 and 169 patients were included from the ZUMA-1 and ZUMA-7 clinical trials, respectively...
April 18, 2024: Blood
https://read.qxmd.com/read/38635661/transcriptome-analysis-of-burkitt-lymphoma-cells-treated-with-anti-convulsant-drugs-that-are-inhibitors-of-epstein-barr-virus-lytic-reactivation
#5
JOURNAL ARTICLE
Kelly L Gorres, David M Reineke, George Miller
Herpesviruses have two distinct life cycle stages, latency and lytic replication. Epstein-Barr virus (EBV), a gamma-herpesvirus, establishes latency in vivo and in cultured cells. Cell lines harboring latent EBV can be induced into the lytic cycle by treatment with chemical inducing agents. In the Burkitt lymphoma cell line HH514-16 the viral lytic cycle is triggered by butyrate, a histone deacetylase (HDAC) inhibitor. Butyrate also alters expression of thousands of cellular genes. However, valproic acid (VPA), another HDAC inhibitor with global effects on cellular gene expression blocks EBV lytic gene expression in Burkitt lymphoma cell lines...
2024: PloS One
https://read.qxmd.com/read/38635572/incidence-rates-of-the-most-common-canine-tumors-based-on-data-from-the-swiss-canine-cancer-registry-2008-to-2020
#6
JOURNAL ARTICLE
Elena Sophie Dhein, Ulla Heikkilä, Anna Oevermann, Sohvi Blatter, Daniela Meier, Sonja Hartnack, Franco Guscetti
Monitoring neoplasms in standardized registries facilitates epidemiologic studies of risk factors for tumor development and predisposition. In an observational study, we determined incidence rates (IR) and malignant tumor incidence rate ratios (IRR) by age, sex, and breed in Swiss dogs using demographic data from the official Swiss dog registration database Amicus. The dataset analyzed included 54'986 tumors diagnosed by histology and cytology in four Swiss veterinary pathology laboratories between 2008 and 2020...
2024: PloS One
https://read.qxmd.com/read/38635491/management-of-relapsed-refractory-mantle-cell-lymphoma
#7
REVIEW
Musa Alzahrani, Diego Villa
In this review we summarize the current evidence describing the management of patients with relapsed/refractory MCL and outline the various novel therapeutics that have been developed over the past two decades. We also describe how overall response rates, complete response rates, duration of responses, and life expectancy have dramatically increased with the introduction of novel therapies, particularly covalent Bruton Tyrosine Kinase inhibitors (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy. The most recent emerging options for patients with progressive disease following BTKi or CAR-T, including non-covalent BTKi, antibody-drug conjugates, Bcl-2 inhibitors, and bispecific antibodies, may further improve response rates and outcomes...
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38635387/prognosis-prediction-of-diffuse-large-b-cell-lymphoma-in-18-f-fdg-pet-images-based-on-multi-deep-learning-models
#8
JOURNAL ARTICLE
Chunjun Qian, Chong Jiang, Kai Xie, Chongyang Ding, Yue Teng, Jiawei Sun, Liugang Gao, Zhengyang Zhou, Xinye Ni
Diffuse large B-cell lymphoma (DLBCL), a cancer of B cells, has been one of the most challenging and complicated diseases because of its considerable variation in clinical behavior, response to therapy, and prognosis. Radiomic features from medical images, such as PET images, have become one of the most valuable features for disease classification or prognosis prediction using learning-based methods. In this paper, a new flexible ensemble deep learning model is proposed for the prognosis prediction of the DLBCL in 18 F-FDG PET images...
April 18, 2024: IEEE Journal of Biomedical and Health Informatics
https://read.qxmd.com/read/38635368/high-remission-rates-and-transition-to-allogeneic-transplant-in-older-patients-with-newly-diagnosed-flt-3-mutated-acute-myelogenous-leukemia-with-midostaurin-plus-intensive-chemotherapy
#9
JOURNAL ARTICLE
Jose Tinajero, Dat Ngo, Jianying Zhang, Ni-Chun Tsai, Ahmed Aribi, Ibrahim Aldoss, Vaibhav Agrawal, Shukaib Arslan, Idoroenyi Amanam, Hoda Pourhassan, Karamjeet Sandhu, Monzr Al-Malki, Vinod Pullarkat, Pamela Becker, Ryotaro Nakamura, Anthony Stein, Guido Marcucci, Andrew Artz, Paul Koller, Amandeep Salhotra
No abstract text is available yet for this article.
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38635308/effectiveness-and-cost-effectiveness-of-survivorship-care-for-survivors-of-hodgkin-lymphoma-insight-study-protocol-for-a-multicenter-retrospective-cohort-study-with-a-quasi-experimental-design
#10
JOURNAL ARTICLE
Eline M J Lammers, Josée M Zijlstra, Valesca P Retèl, Berthe M P Aleman, Flora E van Leeuwen, Annelies Nijdam
BACKGROUND: Hodgkin lymphoma (HL) occurs at young ages, with the highest incidence between 20 and 40 years. While cure rates have improved to 80%-90% over the past decades, survivors of HL are at substantial risk of late treatment-related complications, such as cardiovascular diseases, breast cancer, severe infections, and hypothyroidism. To reduce morbidity and mortality from late treatment effects, the Dutch Better care after lymphoma, Evaluation of long-term Treatment Effects and screening Recommendations (BETER) consortium developed a survivorship care program for 5-year survivors of HL that includes risk-based screening for and treatment of (risk factors for) late adverse events...
April 18, 2024: JMIR Research Protocols
https://read.qxmd.com/read/38635275/use-of-insecticide-treated-bed-nets-and-incidence-of-burkitt-lymphoma
#11
JOURNAL ARTICLE
Thirumalaisamy P Velavan, Peter G Kremsner
No abstract text is available yet for this article.
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38635267/mosquito-bed-net-use-and-burkitt-lymphoma-incidence-in-sub-saharan-africa-a-systematic-review-and-meta-analysis
#12
JOURNAL ARTICLE
Nora Schmit, Jeevan Kaur, Elom K Aglago
IMPORTANCE: Burkitt lymphoma (BL) is one of the most common childhood cancers in sub-Saharan Africa and is etiologically linked to malaria. However, evidence for an effect of malaria interventions on BL is limited. OBJECTIVE: To investigate the potential population-level association between large-scale rollout of insecticide-treated bed nets (ITNs) in sub-Saharan Africa in the 2000s and BL incidence. DATA SOURCES: In this systematic review and meta-analysis, a search was conducted in the Embase, Global Health, and Medline databases and in cancer registry publications between January 1, 1990, and February 27, 2023...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38634916/covid-19-severity-in-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-a-single-center-observational-cohort-study
#13
JOURNAL ARTICLE
Sophie Thau, Christian Bjørn Poulsen, Christian Brieghel, Morten Kranker Larsen, Lothar Wiese, Xiaohui Chen Nielsen, Lars Møller Pedersen
Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023...
April 18, 2024: Annals of Hematology
https://read.qxmd.com/read/38634549/an-odd-dancing-couple-non-small-cell-lung-carcinoma-with-coexisting-egfr-mutation-and-ntrk-1-translocation-a-case-report
#14
JOURNAL ARTICLE
Ramon Robledano, Maria D Lozano
In the 21st century, there has been a dramatic shift in the diagnosis and management of non-small cell lung carcinoma (NSCLC), with an increasing use of minimally invasive tissue acquisition methods. Current treatments require morphologic subtyping and biomarker information in all cases. Determining such biomarkers is a continuously evolving field; current guidelines state that the determination of mutations on the Epidermal Growth Factor (EFGR), Kirsten Rat Sarcoma viral oncogene homolog (KRAS), Proto-oncogene B-Raf (BRAF), Human epidermal growth factor receptor 2 (HER2) and Anaplastic Lymphoma Kinase (ALK), genes as well as fusions on genes such as ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1), MET proto-oncogene, receptor tyrosine kinase (MET), RET proto-oncogene (RET), and the Neurotrophic Tyrosine Receptor Kinase (NTRK) family is mandatory...
April 18, 2024: Diagnostic Cytopathology
https://read.qxmd.com/read/38634529/paraneoplastic-calmodulin-kinase-like-vesicle-associated-protein-camkv-autoimmune-encephalitis
#15
JOURNAL ARTICLE
Michael Gilligan, Connie E Lesnick, Yong Guo, Michael J Bradshaw, Shafeeq S Ladha, Mihaela Nowak, Maulik P Shah, John R Wittenborn, Eati Basal, Shannon Hinson, Binxia Yang, Divyanshu Dubey, John R Mills, Sean J Pittock, Anastasia Zekeridou, Andrew McKeon
OBJECTIVES: To report an autoimmune paraneoplastic encephalitis characterized by immunoglobulin G (IgG) antibody targeting synaptic protein calmodulin kinase-like vesicle-associated (CAMKV). METHODS: Serum and cerebrospinal fluid (CSF) samples harboring unclassified antibodies on murine brain-based indirect immunofluorescence assay (IFA) were screened by human protein microarray. In 5 patients with identical cerebral IFA staining, CAMKV was identified as top-ranking candidate antigen...
April 18, 2024: Annals of Neurology
https://read.qxmd.com/read/38634453/incidence-of-chemotherapy-related-cardiac-dysfunction-in-cancer-patients
#16
JOURNAL ARTICLE
Hai-Wei Deng, Rui Fan, Yuan-Sheng Zhai, Jie Li, Zhi-Bin Huang, Long-Yun Peng
BACKGROUND: Cancer patients are increasingly affected by chemotherapy-related cardiac dysfunction. The reported incidence of this condition vary significantly across different studies. HYPOTHESIS: A better comprehensive understanding of chemotherapy-related cardiac dysfunction incidence in cancer patients is imperative. Therefore, we performed a meta-analysis to establish the overall incidence of chemotherapy-related cardiac dysfunction in cancer patients. METHODS: We searched articles in PubMed and EMBASE from database inception to May 1, 2023...
April 2024: Clinical Cardiology
https://read.qxmd.com/read/38634145/not-all-central-nervous-system-lymphomas-are-created-equal
#17
JOURNAL ARTICLE
Alvaro J Alencar, Juan Pablo Alderuccio
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634119/-tp3-binding-domain-mutations-are-bad-news-in-burkitt-lymphoma
#18
JOURNAL ARTICLE
Mitchell S Cairo
Not available.
April 18, 2024: Haematologica
https://read.qxmd.com/read/38634054/analysis-of-the-treatment-and-prognosis-of-266-cases-of-extranodal-natural-killer-t-cell-lymphoma-nasal-type-in-a-single-medical-center
#19
JOURNAL ARTICLE
Lei Yang, Liqiang Wei, Xin Li, Jia Cong, Jin Ye, Na Yao, Jing Yang, Liang Wang, Jingwen Wang
OBJECTIVE: To assess the impact of different treatment strategies and risk factors on the prognosis of patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL) in a single medical center. METHODS AND ANALYSIS: The clinical features of 266 patients with ENKTL were retrospectively analyzed, among whom those in stages I and II received sandwich therapy, while those in stages III and IV underwent chemotherapy plus autologous hematopoietic stem cell transplantation...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38633973/blastoid-mantle-cell-lymphoma-presenting-as-an-oropharyngeal-mass
#20
Sharina Macapagal, Chalothorn Wannaphut, Toshiaki Takahashi, Thanaboon Yinadsawaphan, Yoshito Nishimura, Jared Acoba
Blastoid mantle cell lymphoma (MCL) is an extremely rare neoplasm with a dismal prognosis. MCL with an initial presentation in the oral cavity has been rarely reported. This report describes a 75-year-old male who presented with an oropharyngeal mass causing dysphonia and intermittent hypoxia. A biopsy and immunophenotyping confirmed MCL, favoring the blastoid variant. Imaging showed a 4.2 cm left oropharyngeal polypoid mass with extensive lymphadenopathy. His prognosis was considered unfavorable with elevated Ki-67 index, blastoid morphology, and p53 positivity of malignant cells...
March 2024: Curēus
keyword
keyword
958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.